PARC Inhibitors

The chemical class of PARC inhibitors, as outlined in this context, encompasses a range of compounds that indirectly influence the function of PARC (CUL9, Cullin-9). These inhibitors primarily target the ubiquitin-proteasome system, a crucial pathway for protein degradation in which PARC is involved. PARC, as part of the cullin family, plays a significant role in the regulation of ubiquitin-mediated protein degradation, and its modulation has broad implications for cellular protein homeostasis.

Proteasome inhibitors like MG132, Bortezomib, Lactacystin, and Velcade are known to impact the proteasome pathway. By inhibiting the proteasome, these compounds can indirectly affect the function of PARC in the protein degradation process. Carfilzomib and MLN2238 (Ixazomib), being selective proteasome inhibitors, also fall into this category. Their action on the proteasome can influence the ubiquitin-proteasome pathway, thus potentially modulating PARC's activity. Epoxomicin, PI-31, Marizomib, and Oprozomib are additional examples of proteasome inhibitors that can indirectly impact PARC's role in ubiquitin-mediated protein degradation. Furthermore, compounds like Withaferin A, which inhibits proteasomal activity, and Chloroquine, known for its effect on autophagy, a process interconnected with the ubiquitin-proteasome system, highlight the diverse mechanisms through which the function of PARC can be modulated. These inhibitors underscore the complex interplay between different cellular degradation pathways and the role of PARC within this framework.